Menopausal SymptomsNCT06899243
Efficacy of CL22205 on Bone Mineral Density and Menopausal Symptoms
A study testing CL22205 in people with Menopausal Symptoms, run by Eetho Brands, Inc.
Trial summary
The purpose of this study is to evaluate the effect of CL22205 on bone mineral density and menopausal symptoms in women. Read more about this study
- Who is it for?
- Ages 55 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Menopausal Symptoms
- What is being tested?
- CL22205
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- No sites listed yet
- Study dates
- 25 Mar 2025to 30 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy females aged between 55 and 65 years with a Body mass index (BMI) of approximately 24 and 29 kg/m2.
- Women with menopausal symptoms (modified Kupperman index scores 15-29), absence of menstrual cycle for past 12-months; follicle-stimulating hormone (FSH) > 30 mIU/mL; estradiol < 30 pg/mL.
- Subjects who are under standard supplementation of Vitamin D3 (cholecalciferol) and calcium carbonate.
- Subjects with osteopenia (T score of spine between -1 and -2.5 in DEXA).
- Must also be experiencing at least two symptoms of menopause, such as sleep disturbances, mood changes, fatigue and lack of energy, changes in sexual function, urinary changes, weight gain, or vaginal changes.
- Subject understands the study procedures and provides signed informed consent to participate in the study.
- Normal vital signs, including electrocardiogram (ECG) and laboratory evaluations (including clinical biochemistry, haematology, lipid profile, thyroid profile and complete urinalysis) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator.
Who cannot join
- Consumption of functional food or supplement that modifies body composition, during or 6 months prior to the study.
- History of cerebrovascular disease, thrombo-embolic disorders, heart attack, or angina at any time or thrombophlebitis within the last 5 years.
- Subjects on anti-coagulant or anti-platelet drugs on a daily basis for any conditions.
- Presence of chronic diseases that prevent the performance of a physical exercise program (disabling arthropathies, moderate / severe chronic lung disease, arrhythmias, etc.).
- High alcohol intake (>2 standard drinks per day), or recreational drugs (such as cocaine, methamphetamine, marijuana, etc.) or psychiatric drug users.
- Smokers or tobacco users.
Show all 22Show fewer
- Inability to understand informed consent.
- Serious or terminal illnesses.
- Fasting blood glucose level >125 mg/dl.
- Subjects with a high blood pressure at screening (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg).
- Subjects who had any hormonal therapy, metformin or any other herbal products in the past 3 months.
- Hypothyroidism, hyperthyroidism, hyperprolactinemia, Cushing's syndrome and congenital adrenal hyperplasia, following a special diet for the past 3 months.
- Taking drugs affecting insulin sensitivity or lipid and hormonal profiles, including glucocorticoids, ovulation-stimulating drugs, anti-obesity, anti-diabetes, anti-hypertensive, anti-estrogenic, anti-androgenic during the last 3 months (except the usual drugs of the subjects).
- Active gall bladder disease, gynaecological (including hysterectomy) or breast surgery in the last 6 months.
- Subjects who are being treated for liver cancer or cirrhosis, chronic renal failure, congestive heart failure.
- Subjects with a systemic disease including tuberculosis, leucosis, collagenosis, multiple sclerosis or other autoimmune diseases.
- History of breast, endometrial, other gynaecological cancer at any time or other cancer within the last 5 years.
- History of hypersensitivity reactions attributed to investigational product (IP) or its components or related products.
- History of positive hepatitis screening including Hepatitis B surface antigen or Hepatitis C virus (HCV) antibodies or subjects with human immunodeficiency virus (HIV) and /or syphilis.
- History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol.
- Participated in a clinical study with an investigational drug or biologic within the last 30 days.
- Any condition that in opinion of the investigator, does not justify the subjects' participation in the study.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: The Effect of CL22205 on Bone Mineral Density and Menopausal Symptoms in Women: A Randomized, Double-blind, Placebo Controlled Clinical Trial
The purpose of this study is to evaluate the effect of CL22205 on bone mineral density and menopausal symptoms in women.
Read the detailed description
A total of 80 healthy female subjects aged between 55 and 65 years will be included in the study. Assessment of inclusion and exclusion criteria will be done based on clinical and laboratory investigations. The eligible subjects will be randomized as per the computer-generated randomization list. The subjects will be assigned to either CL22205 - 200 mg or placebo arms at 1:1 ratio. The subjects will be instructed to take one capsule a day after breakfast for 360 days. Apart from primary and secondary outcomes, the study will also record the vital signs and adverse events to evaluate the herbal composition's safety and tolerability. The safety assessment of the CL22205 will also include routine laboratory investigations on blood, urine and clinical chemistry at screening and the final visit of the intervention.
- Conditions
- Menopausal Symptoms
- Being tested
- CL22205, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CL22205Dietary supplement
200 mg, Route : Oral, One capsule a day after breakfast for 360 days
PlaceboOther
Route : Oral, One capsule a day after breakfast for 360 days
| Study group | Role | What they receive |
|---|---|---|
| CL22205 | Experimental | 200 mg, One capsule a day after breakfast for 360 days Receives: Dietary Supplement: CL22205 |
| Placebo | Other | One capsule a day after breakfast for 360 days Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline to the end of the study period in : Bone Mineral density (BMD) (g/cm2) of Lumbar spine (L1-L4)
A low-dose X-ray is used to assess the bone mineral content (density) in specific areas, such as the lumbar spine at L1-L4 region. The results are typically expressed in terms of the T-score. If T scores ≥-1 signifies healthy bone, a range from -1 to -2.5 indicates osteopenia and a score of ≤-2.5 indicates osteoporosis.
Measured: Screening/Baseline, Days 180 & 360
Secondary outcomes (23)
Change from baseline to the end of the study period in : Lean body mass through DEXA
Dual-energy X-ray absorptiometry (DEXA) uses two X-ray beams with different energies to measure lean body mass in Kilograms. Higher ranges reflect a greater proportion of lean tissue.
Measured: Screening/Baseline, Days 180 & 360
Change from baseline to the end of the study period in : Scores of modified Kupperman index (mKI)
The modified Kupperman Index (mKI) is a tool used to assess the severity of menopausal symptoms. The total score ranges from 0 to 63, calculated as the sum of all items by the weighting factor. Scores ranging from 0-6, 7-15, 16-30, and >30 were used to rate the degree of severity as none, mild, moderate, and severe, respectively.
Measured: Screening, Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in: Hand grip-strength
Grip strength was a measure of muscular strength (in kgs) or the maximum force/tension generated by one's forearm muscles. The Hand grip strength was measured using digital hand dynamometer.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in: Chalder Fatigue Scale (CFS)
The Fatigue Scale, sometimes referred to as the Chalder Fatigue Scale, is a self-administered questionnaire for measuring the extent and severity of fatigue within both clinical and non-clinical, epidemiological populations. Items are rated on a 4-point Likert scale (0, 1, 2, 3), with higher scores indicating greater fatigue. The respondent's global score can range from 0 to 33.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in: Profile of Mood States (POMS-SF)
POMS-SF is a commonly used tool for examining people's emotional states. The total score ranges from 0 to 100. A Total Mood Disturbance (TMD)is calculated by subtracting the vigour score from the total sum of the raw scores for tension, depression, anger, fatigue, and confusion. The lower scores indicative of people with more stable mood profiles.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in: Female Sexual Function Index (FSFI)
The FSFI was developed as a brief, easy-to-administer, self-report tool for assessing key dimensions or domains of sexual function and quality of life in various populations of women. Female Sexual Function Index (FSFI), a widely used tool with six domains (Arousal, Desire, Orgasm, Lubrication, Satisfaction, and Pain). The total FSFI score ranges from minimum score of 2 and maximum score of 36. Greater Scores indicates better sexual function.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in: Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a widely used self-report questionnaire that assesses sleep quality over a one-month time interval. Respondents are asked to indicate how frequently they have experienced certain sleep difficulties over the past month and to rate their overall sleep quality. Scores for each question range from 0 to 3, global PSQI score range of 0-21, with higher scores indicating more acute sleep disturbances.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Menopause Symptoms' Severity Inventory (MSSI-38)
The Menopause Symptoms' Severity Inventory (MSSI-38) is a comprehensive tool used to assess menopausal symptoms in terms of both frequency and intensity. MSSI-38 is scored using a five-point Likert scale. The total score ranges from 0 to 152. As the score increases, severity and intensity of menopausal symptoms increases.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Mini Cog Questionnaire (Cognitive function)
The Mini-Cog was one such neuropsychological test that has been effective in detecting patients with dementia. It consists of a three-item recall test and a clock drawing test (CDT). For the three-recall score, ranges from 0-3, and in CDT, subjects were asked to spontaneously draw a circular clock displaying a particular time (11:10). 2 points for a normal clock or 0 (zero) points for an abnormal clock drawing (Lowest possible Score: 0 and the highest possible score: 5). The 3-item recall and clock drawing scores were added together to get the final score. Scores ranges from 0-5, with an increase in score reflect an improvement in cognitive function.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Subject's self-assessment of skin Questionnaire
As the perception of the skin radiance is subjective, a self-assessment has been performed through a questionnaire. The scores range from 0 to 10, with higher scores indicating better skin quality in terms of complexion, smoothness, texture, elasticity, and hydration.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Scores of subjective self-assessment on hair quality
This is a subjective measurement of hair quality by considering the hair fall rate. The Highest Possible Score is 5.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Nail quality related questionnaire (NailQoL)
The Nail Quality of Life (NailQOL) is a measure or assessment used to evaluate how nail condition (such as nail diseases or abnormalities) impacts an individual overall quality of life. NailQOL of 15 questions will be administered and each question will be scored on a 0-100 scale, where 0 = never; 25 = rarely; 50 = sometimes; 75 = often; 100 = all the time. The average total score ranges between 0 and 100. An increase in Nail QoL scores indicates worsening quality of life.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Gastrointestinal symptoms questionnaire (GIS)
GIS questionnaire includes questions about the severity of GI symptoms (Abdominal pain, Epigastric pain, general intestinal symptoms, dysphagia, and stools). The total highest possible Score is 30 and the total lowest possible score is 0.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Perceived Stress Scale (PSS-10)
The perceived stress scale (PSS) is the most widely used psychological questionnaire containing ten questions for measuring the perception of stress. The total highest possible Score is 30 and the total lowest possible score is 0.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Visual assessment of skin wrinkles
Visual assessment of skin wrinkles used to evaluate the appearance of skin aging and to determine the severity of wrinkles. This kind of assessment is typically done by a healthcare professional or dermatologist and involves examining the skin surface to identify and score wrinkles. Grade ranging from 0 to 9 where 0 represents no wrinkles and 9 represents deep wrinkles.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Core Lower Urinary Tract Symptom score (CLSS)
The core lower urinary tract symptom score (CLSS) questionnaire addresses 10 important lower urinary tract symptoms, which are reported as the most influential symptoms that have a negative impact on the QoL of symptomatic men and women. The total score ranges between 0 and 30. Higher scores reflect greater symptom severity.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in: Vaginal pH
The vaginal pH was assessed by using a pH test strip.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Skin hydration using moisture meter
Skin hydration means the moisture content present on the surface of the skin. This will be done by using a moisture meter.
Measured: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Bone specific serum ALP
Bone-specific ALP, produced by osteoblasts, is an enzyme vital for bone mineralization. It's a marker for bone formation and turnover, with elevated levels indicating increased bone formation (e.g., Paget's disease) and decreased levels indicating reduced bone formation (e.g., osteoporosis).
Measured: Baseline/Day 1 & Day 360
Change from baseline to the end of the study period in : Serum Osteoprotegerin
Osteoprotegerin (OPG), produced by osteoblasts, is a key regulator of bone resorption. It inhibits osteoclast differentiation and activity, thereby influencing bone density. OPG also plays a role in vascular calcification and cardiovascular disease. As a marker of bone turnover, elevated OPG levels are associated with increased bone density (e.g., osteopetrosis, Paget's disease), while decreased levels correlate with reduced bone density, osteoporosis, and increased fracture risk.
Measured: Baseline/Day 1 & Day 360
Change from baseline to the end of the study period in : Serum Osteocalcin
Osteocalcin, a protein hormone secreted by osteoblasts, is fundamental to bone mineralization and calcium homeostasis. It promotes calcium deposition, modulates bone resorption, and participates in glucose metabolism and fat mass regulation. As a biomarker of bone formation, elevated osteocalcin levels indicate increased bone turnover (e.g., osteoporosis, Paget's disease), while decreased levels suggest reduced bone formation (e.g., osteomalacia, rickets).
Measured: Baseline/Day 1 & Day 360
Change from baseline to the end of the study period in: Serum cortisol
Cortisol, a steroid hormone synthesized by the adrenal glands, is essential for the body's stress response, glucose regulation, and macronutrient metabolism. Maintaining appropriate cortisol levels is critical for women's overall health.
Measured: Baseline/Day 1 & Day 360
Change from baseline to the end of the study period in: Vaginal dryness
The vaginal dryness intensity was assessed with an analog visual scale (length 10 cm), considering 10 as the maximum vaginal dryness and 0 as symptom absence.
Measured: Baseline/Day 1, Days 90,180 & 360
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2025
- Study start25 Mar 2025 (estimated)
- Primary completion10 May 2026 (estimated)
- Study completion30 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Menopausal SymptomsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eetho Brands, Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Dr Arti Dibya, MBBS, MS DGO, Principal investigator, Vastalya Hospital and multispecialty Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06899243
- Sponsor's protocol ID
- EB/MS/CL22205/24
- Status last verified
- Mar 2025
- First submitted
- 1 Mar 2025
- Last updated
- 27 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of CL22205 on Bone Mineral Density and Menopausal Symptoms in Women: A Randomized, Double-blind, Placebo Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT06899243
- Acronym / sponsor ID
- EB/MS/CL22205/24
- Conditions
- Menopausal Symptoms
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Eetho Brands, IncIndustry (pharma, biotech, devices)
- Study start
- 25 Mar 2025 (estimated)
- Primary completion
- 10 May 2026 (estimated)
- Study completion
- 30 Aug 2026 (estimated)
- First posted
- 27 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effect of CL22205 on bone mineral density and menopausal symptoms in women.
Detailed description
A total of 80 healthy female subjects aged between 55 and 65 years will be included in the study. Assessment of inclusion and exclusion criteria will be done based on clinical and laboratory investigations. The eligible subjects will be randomized as per the computer-generated randomization list. The subjects will be assigned to either CL22205 - 200 mg or placebo arms at 1:1 ratio. The subjects will be instructed to take one capsule a day after breakfast for 360 days. Apart from primary and secondary outcomes, the study will also record the vital signs and adverse events to evaluate the herbal composition's safety and tolerability. The safety assessment of the CL22205 will also include routine laboratory investigations on blood, urine and clinical chemistry at screening and the final visit of the intervention.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CL22205 | Experimental | Dietary Supplement: CL22205200 mg, One capsule a day after breakfast for 360 days |
| Placebo | Other | Other: PlaceboOne capsule a day after breakfast for 360 days |
Who may qualify
- Ages
- 55 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Healthy females aged between 55 and 65 years with a Body mass index (BMI) of approximately 24 and 29 kg/m2.
- Women with menopausal symptoms (modified Kupperman index scores 15-29), absence of menstrual cycle for past 12-months; follicle-stimulating hormone (FSH) > 30 mIU/mL; estradiol < 30 pg/mL.
- Subjects who are under standard supplementation of Vitamin D3 (cholecalciferol) and calcium carbonate.
- Subjects with osteopenia (T score of spine between -1 and -2.5 in DEXA).
- Must also be experiencing at least two symptoms of menopause, such as sleep disturbances, mood changes, fatigue and lack of energy, changes in sexual function, urinary changes, weight gain, or vaginal changes.
Key exclusion criteria (22 listed)
- Consumption of functional food or supplement that modifies body composition, during or 6 months prior to the study.
- History of cerebrovascular disease, thrombo-embolic disorders, heart attack, or angina at any time or thrombophlebitis within the last 5 years.
- Subjects on anti-coagulant or anti-platelet drugs on a daily basis for any conditions.
- Presence of chronic diseases that prevent the performance of a physical exercise program (disabling arthropathies, moderate / severe chronic lung disease, arrhythmias, etc.).
- High alcohol intake (>2 standard drinks per day), or recreational drugs (such as cocaine, methamphetamine, marijuana, etc.) or psychiatric drug users.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CL22205200 mg, Route : Oral, One capsule a day after breakfast for 360 days | Dietary supplement | CL22205 |
| PlaceboRoute : Oral, One capsule a day after breakfast for 360 days | Other | Placebo |
Primary outcome
Change from baseline to the end of the study period in : Bone Mineral density (BMD) (g/cm2) of Lumbar spine (L1-L4)
Time frame: Screening/Baseline, Days 180 & 360
A low-dose X-ray is used to assess the bone mineral content (density) in specific areas, such as the lumbar spine at L1-L4 region. The results are typically expressed in terms of the T-score. If T scores ≥-1 signifies healthy bone, a range from -1 to -2.5 indicates osteopenia and a score of ≤-2.5 indicates osteoporosis.
23 secondary outcomes
Change from baseline to the end of the study period in : Lean body mass through DEXA
Time frame: Screening/Baseline, Days 180 & 360
Change from baseline to the end of the study period in : Scores of modified Kupperman index (mKI)
Time frame: Screening, Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in: Hand grip-strength
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in: Chalder Fatigue Scale (CFS)
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in: Profile of Mood States (POMS-SF)
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in: Female Sexual Function Index (FSFI)
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in: Pittsburgh Sleep Quality Index (PSQI)
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Menopause Symptoms' Severity Inventory (MSSI-38)
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Mini Cog Questionnaire (Cognitive function)
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Subject's self-assessment of skin Questionnaire
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Scores of subjective self-assessment on hair quality
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Nail quality related questionnaire (NailQoL)
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Gastrointestinal symptoms questionnaire (GIS)
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Perceived Stress Scale (PSS-10)
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Visual assessment of skin wrinkles
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Core Lower Urinary Tract Symptom score (CLSS)
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in: Vaginal pH
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Skin hydration using moisture meter
Time frame: Baseline/Day 1, Days 90,180 & 360
Change from baseline to the end of the study period in : Bone specific serum ALP
Time frame: Baseline/Day 1 & Day 360
Change from baseline to the end of the study period in : Serum Osteoprotegerin
Time frame: Baseline/Day 1 & Day 360
Change from baseline to the end of the study period in : Serum Osteocalcin
Time frame: Baseline/Day 1 & Day 360
Change from baseline to the end of the study period in: Serum cortisol
Time frame: Baseline/Day 1 & Day 360
Change from baseline to the end of the study period in: Vaginal dryness
Time frame: Baseline/Day 1, Days 90,180 & 360
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2025.
- Individual participant dataSharing planned: No
Related trials for Menopausal Symptoms
Recruiting
Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES)
Menopause, Perimenopause
Not yet recruitingPhase 4
Migraine Menopause Study
Migraine, Menopausal
RecruitingPhase 3
A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause
Hot Flashes
Not yet recruitingPhase 3
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
Obesity
Not yet recruiting
A Clinical Trial to Evaluate the Effects of A Supplement on Symptoms of Menopause and Overall Well-being
Menopause, Menopausal Symptoms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dr Arti Dibya, MBBS, MS DGO principal investigator
Vastalya Hospital and multispecialty Centre
Questions about this trial
What is this clinical trial studying?
A study testing CL22205 in people with Menopausal Symptoms, run by Eetho Brands, Inc.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Vasu Goyal (2125550199, eethos.c@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline to the end of the study period in : Bone Mineral density (BMD) (g/cm2) of Lumbar spine (L1-L4) (time frame: Screening/Baseline, Days 180 & 360). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2025.